Time filter

Source Type

Saint-Antoine-du-Rocher, France

Pilon A.,University Paris - Sud | Pilon A.,Hopitaux Universitaires Of Lest Parisien | Pous C.,University Paris - Sud | Pous C.,Hopitaux universitaires Paris Sud
Medecine/Sciences | Year: 2013

Cytoplasm organization greatly depends on the cytoskeleton and especially on microtubules. Their multiple roles comprise for instance long-distance vesicular traffic or the organization of several signalling pathways. A variety of cellular functions require highly dynamic microtubules, which alternate between growing and shrinking phases. Meanwhile, other functions use stable microtubules, in which tubulin often bears multiple post-translational modifications like acetylation. Recent progress has been made in understanding some molecular mechanisms that control microtubule dynamics or tubulin acetylation. These mechanisms reveal the high plasticity of microtubules and point out the importance of their compartmentalization at structural and functional levels.

Renet S.,Groupe Hospitalier la Pitie Salpetriere | Renet S.,University Paris - Sud | Maritaz C.,Groupe Hospitalier la Pitie Salpetriere | Lotz J.-P.,Hopitaux Universitaires Of Lest Parisien | And 4 more authors.
Bulletin du Cancer | Year: 2016

Summary The care pathway of cancer patients is complex and therefore difficult to define. The oral anticancers (AKPO) have shown their benefits to patients and health professionals, however, the risks induced on the care pathway remain unknown. The objective of the study is to define, quantify the risks from AKPO and their effects on the care pathway (breakdown [Ds], rupture [Rt]). From the proposed care pathway model, FMEA method is used to analyze risks. For the 3 identified processes (1 monotherapy, 2 bitherapies: 2 AKPO or 1 AKPO/1 AKIV), analysis revealed an average of 91 risks, 173 Ds, 147 Rt, increased for 1 AKPO/1 AKIV therapy. The administration and delivery are the most risky steps. The lack of training and information of patients and healthcare professionals generates 80% of Ds and Rt. This model confirms the complexity, variability of the care pathway. The development of actions to improve town-hospital coordination and exchange of information is required to optimize and secure the route, confirming the objectives of "Plan Cancer 3". © 2015 Société Française du Cancer.

Aubard Y.,Limoges University Hospital Center | Poirot C.,Hopitaux Universitaires Of Lest Parisien
Journal de Gynecologie Obstetrique et Biologie de la Reproduction | Year: 2013

We reviewed the studies about fertility-sparing in young patient presenting a benign ovarian tumor. It appears that more than the histologic nature of the ovarian cysts, it is the surgical treatment of the cyst which may decrease fertility. Some good practice of surgical procedures must be kept in mind when one manages a benign ovarian tumor in a young patient wishing to preserve her fertility: surgery should be avoided as much as possible; kystectomy is better than oophorectomy; no radical surgery should be done without pathological certitudes; electrocoagulation must be avoided on the cyst walls. In some situations, fertility is specially endangered: bilateral ovarian cysts, recurrence or strong probability of recurrence (endometriomas), poor ovarian reserve (previous chemo- or radiotherapy, age > 35, premature ovarian failure). In these situations, a pre-operative assessment of the ovarian reserve could be useful. Beside the surgical 'good procedures', gamete cryopreservation procedures could be used. Cryopreservation of mature oocytes (after ovarian hyperstimulation) or in vitro mature oocytes (after antral follicle retrieval) can be proposed. Ovarian tissue cryopreservation is another option. Oocyte (or embryos) cryopreservation can be proposed before or after the surgery. The global management of benign ovarian tumors in young patients should be decided between surgeons and specialists in reproductive biology. © 2013 Elsevier Masson SAS. All rights reserved.

Launay-Vacher V.,Service Icar | Scotte F.,Service dOncologie Medicale | Scotte F.,University of Paris Descartes | Antoine E.-C.,Service dOncologie Medicale | And 2 more authors.
Journal de Pharmacie Clinique | Year: 2015

Among solid tumors, breast cancer has been a model of the benefit of targeted therapies, particularly with trastuzumab which reversed the prognosis of patients with HER-2 positive tumor, opening the way to the development of other anti-HER2 targeted therapies and a antibody-drug conjugate. The past two years have seen the arrival of a specific pharmaceutical form of trastuzumab, allowing subcutaneously and fixed-dose administration. Attention has also been paid to a second targeted biotherapy in breast cancer: bevacizumab. Data from IMELDA and TANIA studies pose questions, and provide answers, on the administration sequence as compared to chemotherapy and the maintenance of antiangiogenic pressure using bevacizumab in this type of tumor. We propose here a review of data from the past two years on these two drugs in this indication.

Fotiou D.,National and Kapodistrian University of Athens | Gerotziafas G.,French Institute of Health and Medical Research | Gerotziafas G.,Hopitaux Universitaires Of Lest Parisien | Kastritis E.,National and Kapodistrian University of Athens | And 2 more authors.
Expert Review of Hematology | Year: 2016

Introduction: Patients with multiple myeloma (MM) have an increased risk of venous thromboembolic (VTE) complications. The first reports of high VTE rates date back to 1999 but became more apparent with the introduction of novel agents in the treatment of MM and mostly with immunomodulatory drugs (IMiDs; thalidomide, lenalidomide and pomalidomide). Areas covered: Currently thromboprophylaxis is recommended for patients who receive IMiDs-based regimens and the type of thrombophrophylaxis is based on patient-, disease- and treatment-related risk factors. Making the distinction between the intrinsic risk of thrombosis in MM and the effect of therapy is crucial. The use of aspirin, low molecular weight heparins and warfarin are the recommended drugs but despite their appropriate use the rates of VTE are not completely eliminated. Expert commentary: Research into biomarkers of increased coagulability and their incorporation in risk assessment models could identify patients most likely to benefit from thromboprophylaxis but such models are not widely used in myeloma. © 2016 Informa UK Limited, trading as Taylor & Francis Group.

Discover hidden collaborations